Concept of flexibility acting as driving force behind industry’s swift response to COVID-19.
How cognitive evaluations can aid in meeting the growing demand for more comprehensive safety profiles.
Three key considerations for deploying technology to help increase diversity in trials.
Optimizing feasibility through increased data collection.
Trials that address multiple questions simultaneously using a master protocol can be operationally complicated. These complexities can be managed, even in studies used to support a marketing application.
Key takeaways from a survey of 250 oncology patients measuring COVID-19’s impact on patient willingness to participate in clinical trials.
Distinguishing CAR-T and CPI approaches and the clinical trial challenges and complexities associated with each.
This eBook will discuss three key ways that researchers can implement AI to address data challenges, improve patient safety and outcomes, and accelerate processes.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
Alleviating sponsor and investigator concerns around sharing of remote-assessment data in accordance with GCP and GDPR standards.
Eliminating barriers to engage underrepresented populations.
By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.
Reliable internet connection an integral part of movement to DCTs.
Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.
A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.
It takes a village to raise a trial, but most stakeholders are siloed on isolated islands.
Strong collaboration critical as trial development advances.
The emergence of AI-powered simulants in improving study efficiency.
eTMF-blockchain technology offers a myriad of application benefits to data quality and integrity while ensuring compliance to ethical standards.
Decentralized trials provide promise for lowering barriers in participation, but industry must continue to be proactive in patient centricity.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Optimizing feasibility through increased data collection.
The diversified sources of the somatic cells call for additional oversight to prevent the introduction, transmission, and spread of communicable disease.
Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.
With an increasing amount of diverse data that must now be collected and analyzed, the industry is faced with increasingly complex studies that present new challenges in data management.
Study seeks to understand how different forms of data meet the needs of researchers.
Webinar Date/Time: Wed, Oct 30, 2024 11:00 AM EDT
Findings from the most recent Biopharma Confidence Index show that the pandemic has substantially influenced biopharma executives’ expectations in key areas like artificial intelligence/machine learning and real-world evidence.